Status:
COMPLETED
Molar Potency Study of HM12460A in Healthy Subjects
Lead Sponsor:
Hanmi Pharmaceutical Company Limited
Conditions:
Healthy Volunteers
Eligibility:
All Genders
18-60 years
Phase:
PHASE1
Brief Summary
This is a phase 1 study to assess and compare molar potency of HM12460A and glargine in healthy subjects.
Eligibility Criteria
Inclusion
- Females must be non-pregnant and non-lactating
- Males must be surgically sterile or using an acceptable contraceptive method
Exclusion
- History of any major surgery within 6 months prior to screening
- Use of any new prescription or non-prescription drug in the last 30 days
Key Trial Info
Start Date :
October 24 2017
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
February 8 2018
Estimated Enrollment :
38 Patients enrolled
Trial Details
Trial ID
NCT03330314
Start Date
October 24 2017
End Date
February 8 2018
Last Update
August 12 2020
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Hanmi Investigative Site
Chula Vista, California, United States, 91911